May 14, 2018 / 6:12 AM / 12 days ago

Takeda posts 55 pct jump in annual profit, beats estimates

TOKYO, May 14 (Reuters) - Japan’s Takeda Pharmaceutical Co Ltd reported on Monday a 55.1 percent jump in annual operating profit, buoyed by growing sales of bowel disease drug Entyvio and heartburn and ulcer drug Takecab.

Operating profit came in at 241.8 billion yen ($2.21 billion) for the year ended March, versus 155.9 billion yen a year ago. That was above an average estimate of 235.4 billion yen from 11 analysts polled by Thomson Reuters I/B/E/S.

For the current financial year, Takeda sees an operating profit of 201 billion yen.

The earnings come days after it agreed to acquire London-listed Shire for $62 billion in a deal that will propel it into the top 10 rankings of global drugmakers. ($1 = 109.3600 yen) (Reporting by Sam Nussey; Editing by Edwina Gibbs and Himani Sarkar)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below